Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase
Not applicable
Started
2026-05-15
Last updated
2026-04-08
Condition(s) studied
Non-erosive Reflux Disease (NERD)
Investigational drug(s) / intervention(s)
Chaizhi Hewei DecoctionPlacebo
Chaizhi Hewei Decoction: Chaizhi Hewei Decoction Granules, 1 packet per dose, twice daily, take 1 hour after breakfast and dinner, course duration: 4 weeks.
Placebo: Placebo, 1 packet per dose, twice daily, to be taken 1 hour after breakfast and dinner, with a course duration of 4 weeks.
Study summary
This study focuses on patients with NERD (gastroesophageal reflux disease) and liver-gallbladder disharmony syndrome as its research subjects. It conducts a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of the Chai Zhi He Wei formula in terms of symptom improvement, quality of life, and adverse reactions. On one hand, this research aims to enhance the level of evidence-based medicine for TCM syndrome differentiation and treatment of NERD. On the other hand, it seeks to reduce the dosage of PPIs (proton pump inhibitors) or discontinue their use, addressing the side effects caused by PPI overuse, and serving as a leading example for TCM clinical research. Lastly, the study aims to optimize the efficacy of Tongjiang granules and address potential safety concerns, such as diarrhea.
Eligibility
Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria:
1. Meet thediagnosis criteria for NERD;
2. GERD Q scale score \>8 points;
3. Meet the criteria for the liver-stomach disharmony syndrome in traditional Chinese medicine;
4. Age between 18-70 years old;
5. Participants are informed and voluntarily sign the informed consent form. -
Exclusion Criteria:
1. Patients with active gastric or duodenal ulcers, gastritis with active bleeding, severe dysplasia of the gastric mucosa, or suspected malignancy; patients with achalasia or post-achalasia surgery; and patients with functional heartburn.
2. Patients with severe primary diseases of the cardiovascular, hepatic, renal, hematological, or respiratory systems, or malignant tumors.
3. Patients with mental disorders (e.g., schizophrenia, bipolar affective disorder, depression, anxiety, obsessive-compulsive disorder) and those with intellectual or language impairments.
4. Pregnant or breastfeeding women.
5. Patients allergic to any components of this preparation.
6. Patients currently taking medications that may affect the outcome of this study (e.g., proton pump inhibitors, potassium-competitive acid blockers, Tongjiang granules, etc.).
7. Patients currently participating in or having participated in other drug clinical trials within the past 4 weeks.
8. Patients with suspected or confirmed history of alcohol or substance abuse, anxiety, or depression; or, according to the investigator's judgment, other conditions that may reduce the likelihood of enrollment or complicate the enrollment process, such as frequent changes in work environment that may lead to loss of follow-up.
\-
Primary outcome measure(s)
Gastroesophageal Reflux Disease Questionnaire (GERD Q) Score — week 0 and the end of treatment at 4 weeks
Trial sites (1)
Facility
City
Region
Status
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Beijing
Beijing Municipality
More Xiyuan Hospital of China Academy of Chinese Medical Sciences trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.